Abbott Laboratories (ABT) $98.83
Abbott is finally shaking off its post-pandemic lethargy, but a 28% discount from its highs suggests the market is still pricing in a skepticism that the underlying data doesn’t support.
52-wk High $137.49
📌 Investment Snapshot
- Trading at $98.83 with a 27.7x P/E, representing a premium to medical device peers.
- Latest Q1 revenue of $11.16B with EPS of $0.62 shows steady core growth.
- Free cash flow of $0.9B supports a healthy 2.82% dividend yield.
- Consensus target of $116.54 implies nearly 18% upside from current levels.
⏳ WAIT
Abbott is currently trapped between a bullish short-term recovery and a bearish long-term trendline. While the 100/100 Technical Confluence Score is impressive, the RSI of 61.7 warns of diminishing near-term momentum.
| 📍 Entry Zone | $94.50 or below | 🛑 Stop-Loss | $88.50 |
| 📋 Adjust If | Price breaks above SMA200 ($108.45) on high volume. | ||
The Investment Case — Why Now?
Over the last 90 days, Abbott has successfully pivoted its narrative from COVID-testing reliance to its high-growth medical device portfolio, specifically the FreeStyle Libre system. The stock has clawed back 9.8% in the last month alone, signaling that institutional accumulation is finally outweighing retail exhaustion. This rotation suggests that the ‘valuation floor’ has moved from the low $80s to the $90 psychological level.
The primary risk remains the 4.57% 10Y Treasury yield, which continues to pressure high-multiple healthcare stocks. If the Fed maintains a hawkish stance through late 2026, Abbott’s 27.7x P/E could face a compression toward 22x, implying a potential $80 price floor. Can Abbott’s pipeline innovation outpace the drag of a ‘higher-for-longer’ interest rate environment?
🤔 Can Abbott’s pipeline innovation outpace the drag of a ‘higher-for-longer’ interest rate environment?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| Dividend Yield | 2.82% |
| Short Interest | 1.5% |
Open chart on TradingView →
📈 Price Action & Technicals
Golden Cross
Inside VA
Buy-side Sweep at $89.97 (2026-07-15)
The price is currently trading above the SMA50 ($88.78) but remains significantly below the SMA200 ($108.45). This gap confirms a medium-term downtrend that has yet to be fully neutralized by the recent rally.
A MACD bullish crossover occurred recently, supported by an ADX of 27.0, which indicates a strengthening trend. However, the RSI at 61.7 suggests that the easiest gains of this leg have already been realized.
The Anchored VWAP at $89.25 and the Volume Profile POC at $90.07 create a formidable support cluster. Any pullback to this $89-$90 zone would likely see aggressive institutional bidding.
Recent liquidity sweeps at $89.97 and $94.54 reveal a market that is actively clearing out weak hands before making a move. The volume ratio of 2.23x confirms that this latest move higher has significant conviction behind it.
Historically, when ABT trades at the upper Bollinger Band ($97.94) while below its SMA200, it often undergoes a 3-5% consolidation. Expect a brief period of sideways churn before the next attempt at $100.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| ABT | Abbott Laboratories | 27.7x |
| MDT | Medtronic plc | 24.5x |
| BSX | Boston Scientific | 32.1x |
| SPY | S&P 500 Average | 21.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $11.16B | $0.62 | +0.2% |
| Q4 2025 | $11.46B | $1.02 | +4.1% |
| Q3 2025 | $11.37B | $0.95 | +3.8% |
| Q2 2025 | $11.14B | $1.02 | +2.5% |
Abbott generated $0.9B in Free Cash Flow last quarter, maintaining its status as a cash cow despite R&D headwinds. The company returned $0.2B to shareholders via buybacks, though this is a decelerating trend compared to 2024.
Revenue has plateaued near the $11.2B mark for four consecutive quarters, suggesting a need for a new product catalyst. While EPS remains stable, the market is looking for a breakout in the Medical Devices segment to justify a higher P/E multiple.
🚀 Growth Drivers — What Moves the Stock
- FreeStyle Libre 3 Expansion 🟡 Priced In — Continued dominance in the CGM market with expanding insurance coverage for non-insulin users.
- Lingo Consumer Biowearable 🟢 Upside Surprise — The launch of Lingo in the US market could tap into the $30B wellness tech sector.
- M&A Optionality 🟢 Upside Surprise — With a strong balance sheet, Abbott is positioned to acquire smaller cardiovascular tech firms.
🤔 Will the Lingo biowearable be a true mass-market success or just a niche product for athletes?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 145,687 |
| Vanguard Capital Management LLC | 112,949 |
| State Street Corporation | 79,575 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| STRATTON JOHN G. | Director | 2026-05-07 | Purchase | 2000 |
| STARKS DANIEL J | Director | 2026-04-27 | Purchase | 10000 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 1.5% | 1.7 |
⚠ Key Risk Factors
~$2B impact
~$1.5B impact
🎯 Guidance & Wall Street View
Management has signaled mid-single-digit organic sales growth for the remainder of 2026, excluding COVID-related declines. They expect margin expansion as supply chain efficiencies fully materialize.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $135.00 | $116.54 | $92.00 | 24 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| RBC Capital | Outperform | $125 | 2026-07-17 | Reiterated |
| BTIG | Buy | $120 | 2026-07-17 | Maintained |
Wall Street remains overwhelmingly bullish, with 24 analysts maintaining a ‘Buy’ consensus. The mean target of $116.54 suggests that the current price is a significant undervaluation of Abbott’s long-term earnings power.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- FreeStyle Libre 3 adoption accelerates beyond expectations.
- Successful integration of new cardiovascular tech acquisitions.
📊 Base Case
Abbott maintains steady 5-7% organic growth and continues its dividend aristocrat status.
🐻 Bear Case
- GLP-1 drugs significantly reduce demand for diabetes monitoring.
- Macro headwinds force a P/E compression to sub-20x levels.
🎯 Investor Action Plan — By Profile
The stock is currently overextended relative to its SMA50. Wait for a retracement to the Bullish FVG zone between $89.86 and $94.99 before initiating a position.
If you own ABT, stay in the trade. The 100/100 technical score suggests the path of least resistance is up, but new money should wait for a better risk/reward entry.
For those with a 3-5 year horizon, the 2.82% yield and 18% upside to consensus targets make this a core healthcare holding. Accumulate on any dips below $95.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Is Abbott Laboratories still a COVID-19 play?
No, COVID-related testing revenue has largely been phased out of the growth narrative, with the market now focused on core medical devices and nutrition.
Q: What is the key technical level to watch for ABT?
The SMA200 at $108.45 is the ultimate ‘line in the sand.’ A daily close above this level would signal a shift back into a long-term bull market.
Q: Does Abbott's dividend appear safe?
Yes, with a payout ratio well within historical norms and $0.9B in quarterly free cash flow, the dividend is extremely secure.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 For real-time updates and advanced charting tools,
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Abbott Laboratories faces risks from regulatory changes and competition in the medical device sector.
All active positions and their real-time performance are tracked on our Investment Log.
#ABT #AbbottLabs #HealthcareStocks #MedicalDevices #StockMarket2026 #DividendGrowth #Investing